The global HPV testing and Pap test market is projected to reach USD 4.52 billion by 2020 from USD 3.29 billion in 2015, at a CAGR of 6.6% from 2015 to 2020. Cervical cancer is the second most common type of cancer in women, preceded by breast cancer. HPV, a sexually transmitted virus, has been clinically proven to be the primary cause of cervical cancer. HPV contributes to around 90% of all anal and cervical cancers and 70% of vaginal and vulvar cancers. Pap tests are the most preferred tests to detect cervical cancer. These tests include microscopic observation of specimens. However, these tests are unable to detect all the genotypes causing HPV infections and might also lead to a significant number of false negative results. Owing to these challenges posed by Pap tests, HPV diagnostic tests were introduced as effective molecular diagnostic tests.

Market Dynamics

Drivers

Increasing number of cervical cancer cases and growing aging population

Increasing awareness of cervical cancer screening programs

Government initiatives and funding.

Restraints

Changes in regulatory guidelines for cervical cancer screening

HPV vaccination

Opportunities

Introduction of HPV primary screening tests

Challenges

Uncertain reimbursement scenario

Increasing number of cervical cancer cases and growing aging population

Cervical cancer is considered to be the fourth most prevalent forms of cancer globally, and is the most common cause of death among women (Source: Global Cancer Facts and figures). It has been estimated that 527,624 new cases of cervical cancer have emerged worldwide, while 265,653 women died due to cervical cancer in 2012. This figure is expected to reach to 609,270 new cases and 315,727 deaths by 2020. (Source: Globocan 2012). Approximately 26,000 new cancers attributable to HPV occur each year, 18,000 among females and 8,000 among males (Source: CDC). The growing number of cervical cancer cases results in the need for new, technically advanced, and less expensive screening programs. This in turn is expected to drive the HPV testing and Pap test market in the coming years.

Objectives Of The Study

To define, describe, and segment the global HPV testing and Pap test market on the basis of test types, application, end user, and region

To provide detailed information regarding the major factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)

To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global HPV testing and Pap test market

To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market players

To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW)

To profile the key players in the market and comprehensively analyze their market positions and core competencies

To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnership and collaborations in the HPV testing and Pap test market

Research Methodology

Both, top-down and bottom-up approaches were used to validate the size of the global HPV testing and Pap test market and estimate the size of various other dependent submarkets. Major players in the market were identified through secondary research and their market presence was studied through primary and secondary research. Secondary research included the study of the annual and financial reports of top market players, presentations, websites, and press releases of top players, news articles, journals; and paid databases ,white papers, medical journals, certified publications, articles from recognized authors, directories, and databases such as American Cancer Society (ACS), American Society for Colposcopy and Cervical Pathology (ASCCP), Centers for Disease Control and Prevention (CDC), National Breast and Cervical Cancer Early Detection Program (NBCCEDP), National Cervical Cancer Coalition (NCCC), Ontario Cervical Screening Program (OCSP). Whereas, primary research included extensive interviews with key opinion leaders such as CEOs, vice presidents, directors, marketing executives, and related key executives from various companies. The percentage splits, shares, and breakdowns of the segments were determined using secondary sources and verified through primary sources. This data is consolidated and added to detailed inputs and analysis from MarketsandMarkets and presented in this report.

To know about the assumptions considered for the study, download the pdf brochure

Key players in the HPV testing and Pap test market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.).



Major Market Developments

In April 2014, Roche received the U.S. FDA approval for its cobas HPV (Human Papillomavirus) Test, which is used as a first-line primary screening test for cervical cancer in women.

In February 2014, BD Diagnostics received the CE/IVD marking for the BD Onclarity HPV Assay that can be used on the new BD Viper LT System

In September 2015, QIAGEN introduced careHPV Test and digene HC2 Collection Device for the HPV screening process in women.

IN February 2014, QIAGEN expanded commercial launch of careHPV test in India, a molecular diagnostic test for high risk human papillomavirus (HPV), a primary cause of cervical cancer in woman.

Target Audience:

Molecular Diagnostic Instruments & Assays Manufacturers And distributors

In vitro Diagnostic (IVD) Companies

Hospital Laboratories

Reference Laboratories

Pharmaceutical and Biotechnology Companies

Research and Consulting Firms

Health Insurance Players

Physicians

Scope of the Report

The research report categorizes the global HPV testing and Pap test market into the following segments and subsegments:

HPV testing and Pap test market, by test type

HPV Testing Follow-up HPV Testing Co-testing HPV Primary testing

Pap Test

HPV testing and Pap test market, by application

Pap Test Cervical Cancer Screening Vaginal Cancer Screening



HPV testing and Pap test Market, by end user

Laboratories

Hospitals

Physician�s Offices & Clinics

Global HPV testing and Pap test Market, by Region

North America US Canada

Europe

Asia Pacific Japan India China Rest of Asia (RoAPAC)

Rest of the World (RoW)

Available customizations

Company Information

Detailed analysis and profiling of additional market players (up to 5)

Geographic Analysis

Detailed analysis of HPV testing and Pap test market in European countries such as the UK, Germany, France, Italy, Spain, and others

With the given market data, MarketsandMarkets offers customizations as per the company�s specific needs. The following customization options are available for the report:

The Papanicolaou test (Pap test) is a screening test used to detect pre-cancerous cells in the endocervical canal of the female reproductive system. Pre-cancerous cells might change into cancerous cells, if they are not diagnosed at an early stage. Pap tests are usually used to screen for cervical cancer, but sometimes vaginal cancer cells can also be detected on a Pap test. The HPV test is used to diagnose the infection caused by HPV that mutates a normal cell into a cancerous cell and further leads to the development of genital warts, abnormal cervical cells, or cervical cancer. The growth of the HPV testing and Pap test market is mainly attributed to the increasing number of cervical cancer cases, growing aging population, increasing awareness of cervical cancer screening programs, and government initiatives and funding.

In this report, the global HPV testing and Pap test market is broadly segmented by test type, application, end user, and region.

The HPV testing and Pap test market is broadly segmented into HPV testing and Pap test market. Among HPV testing and Pap test, HPV testing is preferred due to its broad application in cervical cancer screening and increasing awareness of this screening procedure. The HPV testing market is further segmented into follow-up HPV testing, co-testing, and HPV primary testing. The HPV primary testing segment is expected to grow at the highest CAGR during the forecast period. Growing incidences of cervical cancer, higher consistency and effectiveness of HPV primary tests, and approval for Roche�s HPV test as a primary screening method are factors driving the growth of the HPV primary testing market.

Based on the application, the Pap test market is segmented into cervical cancer screening and vaginal cancer screening. The cervical cancer screening segment is expected to grow at the highest CAGR during the forecast period, owing to growing incidences of cervical cancer.

On the basis of end user, the HPV testing and Pap test market is categorized into hospitals, laboratories, physician�s offices and clinics. The hospitals segment is projected to grow at the highest CAGR from 2015 to 2020. This growth is attributed to the increasing patient volumes in hospitals, as most diagnostic tests are carried out in-house with advanced technologies and more accessibility.

Geographically, the HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). North America is expected to grow at the highest CAGR in the forecast period. Increased government funding & grants and introduction of HPV primary tests are major factors fueling the growth of the HPV testing and Pap test market in North America.

However, changes in regulatory guidelines for cervical cancer screening and HPV vaccination are major restraints impacting the growth of the HPV testing and Pap test market

Key players in the HPV testing and Pap test market include Hologic Inc. (U.S.), Qiagen N.V. (Netherlands), F. Hoffmann-La Roche Ltd. (Switzerland), Quest Diagnostics (U.S.), OncoHealth Corporation (U.S.), and Becton, Dickinson and Company (U.S.). These players focus on inorganic and organic strategies such as product approvals & licenses, agreements, collaborations, and partnerships, expansions, acquisitions to sustain their growth in the HPV testing and Pap test market.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst